AI Article Synopsis
- Bladder cancer frequently has genetic changes, especially in the histone demethylase gene, which is often mutated.
- Researchers conducted a thorough review of literature from 2013 to 2022 to analyze the effects of these mutations and explore potential treatments targeting KDM6A.
- The review gathered data from 30 articles, highlighting the importance of KDM6A in bladder cancer development and discussing various therapeutic strategies in organized tables for clarity.
Article Abstract
Bladder cancer is a common urogenital malignancy characterized by frequent genetic alterations. Histone demethylase gene is commonly mutated in bladder cancer. To review the characteristics of and its mutation consequences, and to introduce a potential KDM6A-targeted treatment. We conducted a comprehensive literature search using two electronic databases, MEDLINE and Cochrane Library, to retrieve topic-related articles from July 2013 to July 2022 using keywords 'KDM6A', 'bladder cancer', 'UTX', 'treatment' and 'mutation'. Five reviewers independently screened literature search results and abstracted data from included studies. Descriptive analysis was conducted and 30 articles were retained. A total of 30 articles were retrieved. Experimental and clinical data were collected and grouped by theme. Therapeutic strategies are depicted and organized by tables for a better understanding. This review demonstrates that has crucial implications in bladder cancer pathogenesis and treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pgs-2023-0027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!